Guardant Health, Inc. maintains a bullish outlook, driven by strong oncology segment growth and leadership in liquid biopsy testing. GH delivered FY2025 revenue of $982 million, up 33% YoY, with oncology contributing 67.6% of total revenues and 26% YoY growth. Liquid biopsy adoption is accelerating, offering non-invasive cancer diagnostics and supporting GH's revenue momentum and market outperformance.
Capricorn Fund Managers Ltd boosted its holdings in shares of Guardant Health, Inc. (NASDAQ: GH) by 197.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 107,787 shares of the company's stock after acquiring an additional 71,587 shares
Guardant Health, Inc. (NASDAQ: GH - Get Free Report) has received an average rating of "Moderate Buy" from the twenty-two analysts that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and twenty have assigned a buy recommendation to the company. The
PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that real-world evidence generated from Guardant's InfinityAI contributed to the recent approval of ENHERTU® (trastuzumab deruxtecan), developed and commercialized by Daiichi Sankyo (TSE:4568) in Japan, for the treatment of patients with HER2-positive (HER2 [ERBB2] gene amplification or immunohistochemistry [IHC] 3+) advanced or recurrent solid cancers refractory or into.
Connective Portfolio Management LLC bought a new stake in Guardant Health, Inc. (NASDAQ: GH) in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 7,000 shares of the company's stock, valued at approximately $715,000. Guardant Health accounts for about 1.3% of Connective
Combination of high quality, variable-rich, curated EHR data with genomics enhances understanding of the patient journey and aids in therapy development SAN FRANCISCO, March 24, 2026 /PRNewswire/ -- Verana Health ®, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD), has announced a new partnership with leading precision oncology company Guardant Health Inc. (Nasdaq: GH) that will allow biopharmaceutical researchers to access the combined resources of Verana's regulatory-grade, therapeutic-specific EHR curated datasets from leading medical societies and academic and community medical centers and Guardant's clinicogenomic testing data to accelerate the development of new therapies and enhance on-going patient care. Using the extensive datasets the collaboration provides, research scientists can more easily understand and further validate correlations between molecular biomarkers, treatment decisions and clinical outcomes.
Shares of Gamehost Inc. (TSE: GH - Get Free Report) crossed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of C$11.76 and traded as low as C$11.70. Gamehost shares last traded at C$11.76, with a volume of 5,300 shares trading hands. Gamehost Stock Performance The stock has
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present 28 abstracts, including 3 oral sessions, showcasing advances in methylation-based tumor classification and liquid biopsy technology at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, California taking place April 17 - 22, 2026. Key data that will be presented include: An oral present.
Algert Global LLC raised its holdings in Guardant Health, Inc. (NASDAQ: GH) by 169.1% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 120,114 shares of the company's stock after purchasing an additional 75,474 shares during the period.
PALO ALTO, Calif. & HONG KONG--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of the Shield™ multi-cancer detection (MCD) laboratory developed test (LDT) in multiple markets in Asia. The Shield MCD test is a methylation-based blood test for the detection of multiple cancer types including bladder, colorectal, breast, prostate, esophageal, gastric, liver, lung, ovarian and pancreas cancer in individuals aged 45 or older who a.
